Author:
Jones David R.,McBlane James W.
Reference70 articles.
1. ABPI 2011 First in Human Studies: Points to Consider in Study Placement, Design and Conduct
2. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high risk biologics;Agoram;Br J Clin Pharmacol,2009
3. Safety evaluation to support first-in-man investigations I: kinetic and safety pharmacology studies;Baldrick;Regul Toxicol Pharmacol,2008a
4. Safety evaluation to support first-in-man investigations II: toxicology studies;Baldrick;Regul Toxicol Pharmacol,2008b
5. Nonclinical aspects of biosimilar development - practical considerations from an industry perspective;Baldrick;TOPRA Regul Rapport,2012